Work

Pegilodecakin as monotherapy or in combination with anti-PD-1 or tyrosine kinase inhibitor in heavily pretreated patients with advanced renal cell carcinoma (RCC): Updated results from phase I/Ib IVY study.

Year: 2020

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2020.38.6_suppl.679

Authors: Aung Naing, Kyriakos P. Papadopoulos, Deborah J.L. Wong, Raid Aljumaily, Annie Hung, Manuel Afable, Jong Seok Kim, David Ferry, Alexandra Drakaki, Johanna C. Bendell, Nizar M. Tannir

Institutions: The University of Texas MD Anderson Cancer Center, South Texas Accelerated Research Therapeutics, University of California, Los Angeles, OU Health Stephenson Cancer Center, University of Oklahoma, Eli Lilly (United States), Sarah Cannon, Tennessee Oncology

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3008605276

Cites:

Cited by: 1

Related to: 10